Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,198.86 -868.73 (-1.36%) CMC Crypto 200
1,361.36 +48.73 (+3.71%)
BCRX Jan 2025 5.000 call
| Previous close | 0.9500 |
| Open | 1.9500 |
| Bid | 1.2000 |
| Ask | 1.5500 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.4000 - 1.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.84k |
BenzingaBioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g
GuruFocus.comBioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
ZacksBioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
